Zhejiang Starry Pharmaceutical Co.,Ltd. (SHA:603520)
China · Delayed Price · Currency is CNY 10.38
+0.03 (0.29%)
Feb 4, 2026, 3:00 PM CST
SHA:603520 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,054 | 2,013 | 1,996 | 1,868 | 1,873 | 1,356 |
Other Revenue | 337.09 | 337.09 | 200.4 | 263.61 | 126.7 | 11.24 |
| 2,391 | 2,350 | 2,196 | 2,131 | 2,000 | 1,367 | |
Revenue Growth (YoY) | 0.89% | 7.02% | 3.04% | 6.57% | 46.29% | 4.45% |
Cost of Revenue | 1,944 | 1,920 | 1,688 | 1,629 | 1,255 | 767.3 |
Gross Profit | 446.23 | 430.39 | 507.69 | 502.59 | 744.81 | 599.79 |
Selling, General & Admin | 253.3 | 244.51 | 227 | 216.31 | 150.57 | 150.13 |
Research & Development | 134.1 | 140.67 | 134.56 | 132.61 | 124.58 | 87.84 |
Other Operating Expenses | -8.43 | -15.69 | 5.17 | 14.39 | 15.44 | 11.38 |
Operating Expenses | 385.12 | 367.62 | 356.13 | 363.45 | 303.69 | 252.76 |
Operating Income | 61.11 | 62.77 | 151.57 | 139.14 | 441.12 | 347.03 |
Interest Expense | -87.03 | -96.16 | -102.6 | -92.6 | -73.82 | -92.04 |
Interest & Investment Income | 3.89 | 8.41 | 7.55 | 20.63 | 12.93 | 6.96 |
Currency Exchange Gain (Loss) | -10.57 | -10.57 | 4.61 | -26.98 | -1.39 | 20.77 |
Other Non Operating Income (Expenses) | 10.58 | -7.46 | -7.76 | -11.09 | 1.36 | -1.89 |
EBT Excluding Unusual Items | -22.01 | -43.02 | 53.36 | 29.1 | 380.2 | 280.83 |
Impairment of Goodwill | - | - | - | -114.75 | - | - |
Gain (Loss) on Sale of Investments | -2.11 | -9.61 | -14.1 | 0.88 | 0.16 | 0.76 |
Gain (Loss) on Sale of Assets | -4.54 | -4.01 | 3.03 | -3.39 | -4.02 | -2.45 |
Asset Writedown | -14.65 | -9.71 | -3.84 | - | - | - |
Other Unusual Items | 8.94 | 8.94 | 6.89 | 22.75 | 19.06 | 11.37 |
Pretax Income | -34.14 | -57.17 | 45.35 | -65.4 | 395.39 | 303.7 |
Income Tax Expense | -4.95 | -8.07 | 0.8 | 6.53 | 65.62 | 50.1 |
Earnings From Continuing Operations | -29.19 | -49.1 | 44.55 | -71.93 | 329.77 | 253.6 |
Minority Interest in Earnings | -0.06 | 0 | -0.32 | -3.92 | -6.01 | -14.87 |
Net Income | -29.25 | -49.1 | 44.23 | -75.85 | 323.75 | 238.73 |
Net Income to Common | -29.25 | -49.1 | 44.23 | -75.85 | 323.75 | 238.73 |
Net Income Growth | - | - | - | - | 35.62% | 40.16% |
Shares Outstanding (Basic) | 381 | 409 | 340 | 345 | 344 | 334 |
Shares Outstanding (Diluted) | 381 | 409 | 340 | 345 | 344 | 334 |
Shares Change (YoY) | -6.69% | 20.25% | -1.31% | 0.10% | 3.05% | 0.91% |
EPS (Basic) | -0.08 | -0.12 | 0.13 | -0.22 | 0.94 | 0.71 |
EPS (Diluted) | -0.08 | -0.12 | 0.13 | -0.22 | 0.94 | 0.71 |
EPS Growth | - | - | - | - | 31.60% | 38.89% |
Free Cash Flow | -15.48 | -287.12 | -221.67 | -550.56 | 204.96 | 21.31 |
Free Cash Flow Per Share | -0.04 | -0.70 | -0.65 | -1.60 | 0.59 | 0.06 |
Dividend Per Share | 0.150 | 0.150 | - | 0.500 | 0.357 | 0.357 |
Dividend Growth | 200.00% | - | - | 40.02% | - | 99.94% |
Gross Margin | 18.67% | 18.31% | 23.12% | 23.58% | 37.24% | 43.87% |
Operating Margin | 2.56% | 2.67% | 6.90% | 6.53% | 22.06% | 25.38% |
Profit Margin | -1.22% | -2.09% | 2.01% | -3.56% | 16.19% | 17.46% |
Free Cash Flow Margin | -0.65% | -12.22% | -10.09% | -25.83% | 10.25% | 1.56% |
EBITDA | 309.5 | 281.65 | 331.12 | 297.97 | 594.55 | 473.26 |
EBITDA Margin | 12.95% | 11.98% | 15.08% | 13.98% | 29.73% | 34.62% |
D&A For EBITDA | 248.39 | 218.89 | 179.55 | 158.83 | 153.43 | 126.23 |
EBIT | 61.11 | 62.77 | 151.57 | 139.14 | 441.12 | 347.03 |
EBIT Margin | 2.56% | 2.67% | 6.90% | 6.53% | 22.06% | 25.38% |
Effective Tax Rate | - | - | 1.76% | - | 16.60% | 16.50% |
Revenue as Reported | 2,391 | 2,350 | 2,196 | 2,131 | 2,000 | 1,367 |
Advertising Expenses | - | 111.83 | 85.39 | 60.3 | 8.8 | 4.98 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.